Secondary Packages cannot Protect Liquid Biopharmaceutical Formulations from Dropping-Induced Degradation.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceutical research"
DOI: 10.1007/s11095-021-03073-1
Abstract: PURPOSES Liquid protein-based biopharmaceutical formulations have been reported to form aggregation and protein sub-visible particles (SbVPs) during dropping (Randolph et al., J Pharm Sci 2015, 104, 602). However, effects of secondary package on liquid biopharmaceutical… read more here.
Keywords: liquid biopharmaceutical; biopharmaceutical formulations; formulation; stability ... See more keywords
Simultaneous quantification of polysorbate 20 and poloxamer 188 in biopharmaceutical formulations using evaporative light scattering detection.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2020.113640
Abstract: Polysorbates and Poloxamer 188 constitute the most common surfactants used in biopharmaceutical formulations owing to their excellent protein-stabilizing properties and good safety profiles. In recent years, however, a vast number of reports concerning potential risk… read more here.
Keywords: scattering detection; biopharmaceutical formulations; polysorbate poloxamer; evaporative light ... See more keywords
Nile Red fluorescence spectrum decomposition enables rapid screening of large protein aggregates in complex biopharmaceutical formulations like influenza vaccines.
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.04.066
Abstract: The extensive presence of large (high molecular weight) protein aggregates in biopharmaceutical formulations is a concern for formulation stability and possibly safety. Tests to screen large aggregate content in such bioformulations are therefore needed for… read more here.
Keywords: fluorescence; nile red; biopharmaceutical formulations; protein aggregates ... See more keywords